Well Leveraged: VBI Vaccines Outlines Clinical Trial Progress
NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) — Jeff Baxter, President and CEO of VBI Vaccines Inc. (NASDAQ:VBIV), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, took time to update WSA’s investor […]
